A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours

• Published in: Annals of oncology Vol. 18; no. 5; pp. 925 - 930
• Main Authors: Shamash, J, Powles, T, Mutsvangwa, K, Wilson, P, Ansell, W, Walsh, E, Berney, D, Stebbing, J, Oliver, T
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.05.2007; Oxford Publishing Limited (England)
• Subjects: Adolescent; Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Camptothecin - administration & dosage; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Follow-Up Studies; germ-cell tumour; Humans; Irinotecan; Male; mediastinal; Mediastinal Neoplasms - drug therapy; Mediastinal Neoplasms - pathology; Medical sciences; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Neoplasms, Germ Cell and Embryonal - drug therapy; Neoplasms, Germ Cell and Embryonal - pathology; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - adverse effects; Oxaliplatin; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Pharmacology. Drug treatments; phase 2; relapsed; Survival Analysis; Testicular Neoplasms - drug therapy; Testicular Neoplasms - pathology; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; relapsed; phase 2; mediastinal; germ-cell tumour; Human; Relapse; Enzyme; Mediastinum; DNA topoisomerase; Germ cell tumor; Isomerases; Treatment; Phase II trial

Background: The outcome of patients with germ-cell tumours (GCTs), who relapse more than once or relapse with a mediastinal primary is poor. We have shown that topoisomerase 1 may be an attractive target in relapsed GCT. We investigated the role of irinotecan, paclitaxel and oxaliplatin (IPO) follow...